This article has been updated from a previous version, which incorrectly stated that the company plans to shift its R&D resources toward prostate cancer classification and tissue healing in 2007.   
 
NEW YORK (GenomeWeb News) — Epigenomics, trying to recover from a year in which it lost a significant revenue-generating partner, has streamlined its product-development plans for its DNA-methylation-based screening products, and seeks to strike up “multiple non-exclusive partnerships,” the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.